IRIS
FRUMENTO, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 398
Totale 398
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 398
Totale 398
Salva come PNG Salva come JPEG
Città #
Genova 171
Genoa 114
Rapallo 108
Bordighera 5
Totale 398
Salva come PNG Salva come JPEG
Nome #
A2A-D2 heteromers on striatal astrocytes: Biochemical and biophysical evidence 147
Acute stress induces short- and long-lasting modifications of glutamate transmission in the prefrontal cortex at pre- and peri-synaptic compartments 64
Blocking glutamate mGlu5 receptors with the negative allosteric modulator CTEP improves disease course in SOD1G93A mouse model of amyotrophic lateral sclerosis 40
Nearly 30 years of animal models to study amyotrophic lateral sclerosis: A historical overview and future perspectives. 40
Changes at glutamate tripartite synapses in the prefrontal cortex of a new animal model of resilience/vulnerability to acute stress 38
In-vitro and in-vivo studies depict metabotropic glutamate receptor 5 as a potential pharmacological target to modulate disease progression in ALS 37
Acute Ketamine Facilitates Fear Memory Extinction in a Rat Model of PTSD Along With Restoring Glutamatergic Alterations and Dendritic Atrophy in the Prefrontal Cortex 37
Montelukast improves disease progression in the female SOD1G93A mouse model of ALS by restoring oligodendrocyte maturation and counteracting altered glial reactivity 5
Acute Ketamine Facilitates Fear Memory Extinction in a Rat Model of PTSD Along With Restoring Glutamatergic Alterations and Dendritic Atrophy in the Prefrontal Cortex. 4
Pharmacological blockade of the P2Y-like GPR17 receptor with montelukast delays disease progression by counteracting oligodendrocyte dysfunction in the SOD1G93A mouse model of amyotrophic lateral sclerosis 4
A repurposing approach to improve disease outcome in SOD1G93A mice by counteracting oligodendrocyte dysfunction and neuroinflammation 3
Effects of the in-vivo treatment with the non-selective GPR17 antagonist montelukast on disease outcome in the SOD1G93A mouse model of ALS 3
A repurposing approach to delay disease progression in SOD1G93A mice by counteracting oligodendrocyte dysfunction 2
null 1
In-vivo treatment with the GPR17 antagonist montelukast improves lifespan and delays disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis 1
Totale 426
Salva come PNG Salva come JPEG
Categoria #
all - tutte 1.838
article - articoli 1.255
book - libri 0
conference - conferenze 336
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.429
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202060 10 3 0 4 6 8 9 6 4 6 2 2
2020/202135 1 2 0 2 0 0 0 2 1 21 3 3
2021/202288 3 2 7 0 4 1 11 26 7 9 7 11
2022/2023131 12 12 4 15 14 20 0 4 26 8 15 1
2023/2024112 3 7 7 10 18 41 14 6 4 2 0 0
Totale 426